GlassScriptPhysician profile
Kevin L Klein
NPI 1386633279
$3,472.43
in general payments reported to CMS, 2019-2025
27 companies · $547 in 2025
The $547 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $481 · 2021: $516 · 2022: $356 · 2023: $327 · 2024: $600 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,468 · Education: $6.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,468.27 |
| Education | $6.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $581.94 | 2019-2025 | Repatha, Repatha |
| Philips North America LLC | $373.89 | 2020-2025 | Labosys, (Ck7) Extended Holter, Extended Holter |
| Astrazeneca Pharmaceuticals LP | $334.86 | 2019-2023 | Farxiga |
| Pfizer INC. | $263.27 | 2021-2025 | |
| Boston Scientific Corporation | $245.81 | 2021-2025 | Cds - Mct/Cem Monitoring, Watchman Access System, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $221.26 | 2019-2025 | Lifevest |
| Abbott Laboratories | $173.65 | 2019-2025 | Cardiomems |
| Janssen Pharmaceuticals, INC | $163.15 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.76 | 2020-2024 | Jardiance |
| Astellas Pharma US INC | $121.17 | 2019-2021 | |
| Edwards Lifesciences Corporation | $112.42 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $112.40 | 2019-2025 | Eliquis, Camzyos |
| Regeneron Healthcare Solutions, INC. | $89.42 | 2019 | |
| Sanofi-Aventis U.S. LLC | $85.59 | 2019 | |
| Novo Nordisk INC | $83.63 | 2024-2025 | Wegovy, Ozempic |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $49.50 | 2024 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $48.20 | 2024 | |
| Esperion Therapeutics, INC. | $47.95 | 2022-2024 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $35.32 | 2024 | Arcalyst |
| Cardiovascular Systems INC. | $32.03 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $29.77 | 2021-2023 | Arcalyst |
| Atricure, INC. | $25.00 | 2024 | |
| Lilly USA, LLC | $21.65 | 2025 | Zepbound, Mounjaro |
| Alnylam Pharmaceuticals INC. | $21.20 | 2023 | Onpattro |
| Medtronic, INC. | $19.89 | 2021 | |
| Scpharmaceuticals INC. | $18.16 | 2024 | |
| Ge Healthcare | $16.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.